Darutoside
Based on 1 publication(s) in Google Scholar
Darutoside is an orally effective diterpene compound with significant anti-inflammatory, analgesic, wound healing promotion, and immunomodulatory activities. Darutoside reduces edema and pain responses by inhibiting the expression of COX-2 and the migration of inflammatory cells. It regulates macrophage polarization towards the M2 type by inhibiting the NF-κB pathway, alleviating inflammation and promoting wound healing. Through multi-target regulation of metabolic networks, Darutoside significantly alleviates acute gouty arthritis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 59219-65-7
- Formule: C26H44O8
- Masse moléculaire:484.62
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Darutoside
MoreVoir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
|
COX-2 |
NF-κB |
IL-1β |
IL-8 |
IL-10 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
>25 μM
Compound: 6
|
Inhibition of EGF-induced invasion of human MDA-MB-231 cells by MTT assay
Inhibition of EGF-induced invasion of human MDA-MB-231 cells by MTT assay
|
[PMID: 28302401] |
| RAW264.7 | IC50 |
>100 μM
Compound: 6
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS challenge measured after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS challenge measured after 24 hrs by Griess assay
|
[PMID: 28302401] |
Darutoside (0.1-1 mg/mL, 12 h) significantly inhibits the migration of RAW264.7 macrophages induced by LPS (HY-D1056)[1].
Darutoside (0.1-10 μM, 24 h) inhibits the M1-type macrophage polarization by suppressing the NF-κB signaling pathway (reducing the levels of p-IkK, p-IkB, and p-p65) [2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Darutoside (10-100 μM, local topical application, once daily for a total of 7 days) inhibits local inflammatory responses and significantly promotes wound healing in mouse skin[2].
Darutoside (40 mg/mL, p.o., 2 h before modeling, 6 h and 22 h after modeling for 3 doses) significantly alleviates acute gouty arthritis in rats by inhibiting inflammatory cell infiltration and release, promoting blood circulation and improving immunity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse ear swelling model, mouse paw swelling model and mouse writhing test established in young female Kunming mice with 8 weeks (18-22 g)[1]
-
Dosage:0.2 and 2 mg/kg
-
Administration:Local topical application, once daily for 5 days
-
Result:Significantly reduced earlobe edema at 2 mg/kg.
Significantly alleviated paw edema induced by CFA (HY-153808), increased pain threshold, and reduced inflammatory cell infiltration.
Significantly reduce the number of convulsions induced by Acetic acid.
-
Animal Model:Full-thickness skin defect model established in 7-week-old male C57/BL6 mice[2]
-
Dosage:10, 50, 100 μM (based on 2% Methylcellulose (HY-125861) gel)
-
Administration:Local topical application, once daily for 7 days
-
Result:Showed the most significant healing effect at 50 μM, with a significant increase in the wound healing rate.
Accelerated the migration and growth of epithelial cells at the wound edge.
Significantly reduced the expressions of Inosl, Il1b, Tnfa and Il6 in the wound tissue, and increased the expressions of M2 macrophage markers Mrc1, Tgfb and Il10.
-
Animal Model:Acute gouty arthritis model established in male Wistar rats (8 weeks old, weighing 150 g)[3]
-
Dosage:40 mg/mL
-
Administration:Oral administration (p.o.), 2 h before modeling, 6 h and 22 h after modeling for 3 doses
-
Result:Significantly reduced the volume and thickness of the ankle joint.
Reduced the levels of serum IL-8, TNF-α, IL-1β, NF-κB and uric acid.
Significantly increased the level of the anti-inflammatory factor IL-10.
Chemical Information
-
CAS No. 59219-65-7
-
Appearance Solid
-
Masse moléculaire 484.62
-
Formule C26H44O8
-
Color White to light yellow
-
SMILES
C[C@]12[C@@]3([H])C(CC[C@]1([H])C(C)([C@H](O[C@]4([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO)CC2)C)=C[C@]([C@@H](O)CO)(C)CC3
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mol Immunol
2025 Mar 25:181:129-138. PMID: 40138783
Solvant et solubilité
DMSO : 100 mg/mL (206.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Li YS, et al. Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens makino by inhibiting COX-2 expression and inflammatory cell infiltration. J Ethnopharmacol. 2021 Mar 25;268:113547. [Content Brief]
[2]. Gao L, et al. Darutoside promotes skin wound healing via regulating macrophage polarization. Mol Immunol. 2025 May;181:129-138. [Content Brief]
[3]. Wang J, et al. Revealing the pharmacological effect and mechanism of darutoside on gouty arthritis by liquid chromatography/mass spectrometry and metabolomics. Front Mol Biosci. 2022 Aug 24;9:942303. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0635 mL | 10.3174 mL | 20.6347 mL | 51.5868 mL |
| 5 mM | 0.4127 mL | 2.0635 mL | 4.1269 mL | 10.3174 mL | |
| 10 mM | 0.2063 mL | 1.0317 mL | 2.0635 mL | 5.1587 mL | |
| 15 mM | 0.1376 mL | 0.6878 mL | 1.3756 mL | 3.4391 mL | |
| 20 mM | 0.1032 mL | 0.5159 mL | 1.0317 mL | 2.5793 mL | |
| 25 mM | 0.0825 mL | 0.4127 mL | 0.8254 mL | 2.0635 mL | |
| 30 mM | 0.0688 mL | 0.3439 mL | 0.6878 mL | 1.7196 mL | |
| 40 mM | 0.0516 mL | 0.2579 mL | 0.5159 mL | 1.2897 mL | |
| 50 mM | 0.0413 mL | 0.2063 mL | 0.4127 mL | 1.0317 mL | |
| 60 mM | 0.0344 mL | 0.1720 mL | 0.3439 mL | 0.8598 mL | |
| 80 mM | 0.0258 mL | 0.1290 mL | 0.2579 mL | 0.6448 mL | |
| 100 mM | 0.0206 mL | 0.1032 mL | 0.2063 mL | 0.5159 mL |
Darutoside Related Classifications
HY-N6028 Related Classifications
Powered by Bioz